

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/593,786
		Int'l. Filing Date	March 24, 2005
		First Named Inventor	Katsuhiko KANO
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet	1	of	1
		Attorney Docket Number	350292003100

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1.	US-5,216,128-A	06-01-1993	Novick et al.		
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	2.	FR-2 694 767	02-18-1994	Innotherapie Lab. SA	Translation of abstract	
	3.	JP-08-099902	04-16-1996	Chugai Pharmaceutical Co., Ltd.	Translation of abstract	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	4.	Harris, R.(1995). "Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture." <i>Journal of Chromatography A</i> 705:129-134				
	5.	Hirano, T. et al. (November 6, 1986). "Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin." <i>Nature</i> . 324:73-76				
	6.	Akira, S., et al., (1993). "Interleukin-6 in Biology and Medicine." <i>Advances in Immunology</i> . 54:1-78				
	7.	Lotz, M. et al. (March 1, 1988) "B Cell Stimulating Factor 2/Interleukin 6 is a Costimulant for Human Thymocytes and T Lymphocytes." <i>J. Exp. Med.</i> :167:1253-1258				
	8.	Taga, T. et al. (October 1, 1987). "Receptors for B Cell Stimulatory Factor 2: Quantitation, Specificity, Distribution, and Regulation of Their Expression." <i>J. Exp. Med.</i> :166:957-981				
	9.	Yamasaki, K. et al. (August 12, 1988). "Cloning and Expression of the Human Interleukin-6 (BSF-2/IFN β 2) Receptor." <i>Science</i> .241:825-828				
	10.	Novick, D. et al. (November 1, 1991). "Monoclonal Antibodies to the Soluble Human IL-6 Receptor: Affinity Purification, ELISA, and Inhibition of Ligand Binding." <i>Hybridoma</i> . 10:137-146				
	11.	Huang, Y. et al. (November 5, 1993). "A Monoclonal Anti-Human IL-6 Receptor Antibody Inhibits the Proliferation of Human Myeloma Cells." <i>Hybridoma</i> . 12:621-630				
	12.	Sato, K. et al. (February 15, 1993). "Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth." <i>Cancer Research</i> 53:851-856				
	13.	Johnson, K. A. et al. (2007). "Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain." <i>Analytical Biochemistry</i> 360:75-83				
	14.	International Search Report, mailed June 7, 2005, directed to counterpart International Patent Application No. PCT/JP2005/006229; 2 pages				
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.